Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca shareholders approve £18.7mln CEO pay package
02:31am, Friday, 12'th Apr 2024
AstraZeneca PLC (LSE:AZN) shareholders approved a controversial increase to chief executive Pascal Soriot's pay package yesterday. Over 78% of votes gave the £18.7 million salary and bonus package th
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
07:21pm, Thursday, 11'th Apr 2024
Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.
AstraZeneca offers 7% dividend sweetener on day of crucial pay vote
02:34am, Thursday, 11'th Apr 2024
AstraZeneca PLC (LSE:AZN) has increased its annual dividend by 7%, bringing it up to $3.10 (£2.5) per share. It marks the highest annual dividend increase in recent years, having only shifted from $2
AstraZeneca pay debate exposes disparity in US-UK corporate values
08:46am, Wednesday, 10'th Apr 2024
Tomorrow's shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot's compensation represents a microcosm of the broader debate around executive entitlement and the disparity in corporate valu
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
11:42am, Tuesday, 09'th Apr 2024
The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
10:26am, Monday, 08'th Apr 2024
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
06:56pm, Friday, 05'th Apr 2024
Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session.
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
05:36pm, Friday, 05'th Apr 2024
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
01:16pm, Friday, 05'th Apr 2024
AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.
AstraZeneca cancer trial readout underlines immuno opportunity, suggests broker
09:29am, Friday, 05'th Apr 2024
AstraZeneca positive data from Imfinzi's Phase III ADRIATIC trial follows the raft of positive readouts and approvals across a range of cancer types, notes Shore Capital. Already these have stimulated
AstraZeneca reports 'significant' patient improvement in latest Imfinzi cancer trial
03:21am, Friday, 05'th Apr 2024
AstraZeneca has reported that Imfinzi significantly improved survival rates in the latest trial of the immunotherapy-based blockbuster cancer drug. Results from the Phase III ADRIATIC study in people
AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer
02:43am, Friday, 05'th Apr 2024
Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggressiv
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
01:33pm, Wednesday, 03'rd Apr 2024
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
AstraZeneca leads fallers echoing Wall Street's Medicaid surprise
03:36am, Wednesday, 03'rd Apr 2024
AstraZeneca PLC (LSE:AZN) led the fallers on the main index, down 1.3% and echoing falls seen among US peers overnight. It follows surprise news that federal payment rates to Medicare insurers nex
Are You Looking for a High-Growth Dividend Stock?
12:46pm, Tuesday, 02'nd Apr 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
